Theravance Results and Business Update
- Q4 2023 YUPELRI® (revefenacin) net sales, recognized by Viatris, increased 9% from Q4 2022, reaching an all-time high of $60.6 million1
- Full Year 2023 Viatris Collaboration Revenue increased 18% to $57.2 million
- GAAP Net Loss of $8.5 million in Q4; Achieved goal of profitability on Non-GAAP basis in Q4, with Non-GAAP Net Profit of $1.4 million2
- Completed $325 million capital return program, reducing shares outstanding by 37%
- Ampreloxetine investor event planned for Q2 2024
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.